bioAffinity Technologies, Inc. (BIAF)

History and Background

bioAffinity Technologies, Inc. (BIAF) was founded in 2014. It is a biotechnology company focused on early cancer detection and diagnostics. The company has been focused on the development of its CyPathu00ae Lung test, a non-invasive test for the early detection of lung cancer.

Core Business Areas

• Early Cancer Diagnostics: bioAffinity Technologies' main business segment is the development and commercialization of early cancer diagnostic tests. Currently focused on CyPathu00ae Lung for early lung cancer detection.

Leadership and Structure

Maria Zannes serves as the Chief Executive Officer of bioAffinity Technologies, Inc. The company has a board of directors that oversees its strategic direction and governance.

Key Offerings

• CyPathu00ae Lung: CyPathu00ae Lung is a non-invasive sputum test designed for the early detection of lung cancer. Market share data is not publicly available due to the test being relatively new to the market and commercialization being in early stages. Competitors include companies with liquid biopsy or other early detection diagnostics like Guardant Health (GH), Exact Sciences (EXAS), and Freenome. Revenue data is not publicly available.

Industry Overview

The early cancer detection market is rapidly growing, driven by the need for more accurate and less invasive diagnostic methods. Increasing incidence of cancer and advancements in technology are fueling market growth.

Positioning

bioAffinity Technologies is positioned as a player in the early lung cancer detection market with its non-invasive CyPathu00ae Lung test. Its competitive advantage lies in the potential for improved accuracy and patient compliance compared to traditional methods.

Total Addressable Market (TAM)

The TAM for lung cancer diagnostics is estimated to be in the billions of dollars. bioAffinity Technologies aims to capture a significant portion of this market by providing an accessible and accurate early detection test.

Key Competitors

• GH
• EXAS
• ILMN

Competitive Landscape

bioAffinity Technologies is a smaller player compared to larger diagnostics companies like Guardant Health and Exact Sciences. It needs to establish its presence through clinical validation, commercial partnerships, and market penetration.

Historical Growth: Historical growth is limited due to the company being in the early stages of commercialization. Revenue growth will be dependent on the successful adoption of CyPathu00ae Lung.

Future Projections: Future growth projections are dependent on the successful commercialization and market adoption of CyPathu00ae Lung. Analyst estimates are limited due to the company's early stage.

Recent Initiatives: Recent initiatives include completing clinical validation studies and initiating commercialization efforts for CyPathu00ae Lung. Actively seeking partnerships for expansion.

bioAffinity Technologies is an early-stage biotechnology company with a focus on early lung cancer detection. Its CyPathu00ae Lung test shows promise, but the company faces significant challenges in commercialization, competition, and securing reimbursement. Its financial position is weak and dependent on raising capital, while its market position is still in its infancy.

Data Sources:

• bioAffinity Technologies Investor Relations
• SEC Filings
• Industry Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Market share data is based on available estimates and may not be precise. The financial information and projections are based on publicly available data and analyst consensus estimates. This is not investment advice.